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Abstract
Infection by high-risk human papillomaviruses (HPVs) is considered to be the central cause of invasive cervical cancer. Previously
reported studies have shown that Id genes regulate cell invasion and metastasis in several human carcinomas including cervical cancer.
In order to investigate the correlation between high-risk HPVs and Id genes in human cervical cancer, the presence of high-risk HPVs
and their association with Id gene expression was examined using PCR methods and tissue microarray analyses in a cohort of 44 cervi-
cal cancer patients from Syria. This study showed that high-risk HPVs were present in 42 samples (95%) that represent invasive cervical
cancers and that the most frequent high-risk HPV types in Syrian women were 33, 16, 18, 45, 52, 58, 35, 51 and 31. Furthermore, the
expression of E6 oncoprotein of high-risk HPVs was found to correlate with overexpression of Id-1, but not of Id-2, Id-3 or Id-4 in the
majority of invasive cervical cancer tissue samples. These data suggest that high-risk HPVs can enhance the progression of human cervi-
cal cancer through Id-1 regulation.
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Introduction
High-risk HPVs are important risk factors for human cervical
cancer; approximately 96% of cervical cancers score positive
for high-risk HPVs [1,2]. In addition, the presence of high-
risk HPVs serves as a prognostic factor in early-stage cervical
cancers, and are associated with vascular invasion, lymph
node metastases and tumour size [2–5]. The E6 and E7 on-
coproteins of high-risk HPVs, which are expressed in cervical
cancers, inactivate p53 and pRb tumour suppressors, respec-
tively [6]. E6 facilitates the degradation of p53 through its
association with accessory protein E6-AP, a component of
the ubiquitin proteolytic pathway [7]. E7 proteins of high-risk
HPVs bind to Rb [8], as well as to other pocket proteins,
such as p107 and p130 [9], leading to cell cycle deregulation.
This results in genomic instability and has been implicated in
the transformation of normal cells and the progression of
cancerous cervical cells.
Id (inhibitors of differentiation and DNA binding) genes
are members of the helix-loop-helix transcription factor fam-
ily and have multiple functions including inhibition of
differentiation, induction of proliferation and delaying replica-
tive senescence [10,11]. Moreover, Id-1 and Id-3 have been
indicated as potential oncogenes because they are overex-
pressed in several human cancers including cervical, colorec-
tal, breast, pancreatic and prostate cancer [12–16]. The
up-regulation of Id-1 is clearly associated with more aggres-
sive behaviour of tumour cells, particularly in cervical cancers
[12]. These studies suggest that Id genes play an important
role in the progression of human cervical cancers.
This investigation aims to identify the speciﬁc types of
high-risk HPV infections present in cervical cancers of Syrian
women and their association with Id gene expression and
tumour aggressiveness.
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Materials and Methods
HPV detection and type speciﬁcation
Formalin-ﬁxed, parafﬁn-embedded blocks of cervical tumour
samples were obtained from 44 Syrian patients with an average
age of 57 (range 38–82) years. Formalin-ﬁxed (buffered,
neutral aqueous 10% solution), parafﬁn-embedded cervical
tumour samples were supplied by the Department of Pathol-
ogy, Faculty of Medicine at the University of Aleppo, Syria.
The specimens and data used in this research were approved
by the Ethics Committee of the Faculty of Medicine of Alep-
po University. Five micrograms of puriﬁed genomic DNA
(Qiagen GmbH, Hilden, Germany) were taken from each
sample and analysed for HPVs by multiplex PCR targeted to
the conserved L1 region of the viral genome using PGMY09/
11 L1 primer pools [3,13]. In parallel, speciﬁc primers for
the E7 gene were used to detect HPV types 16, 18, 31, 33,
35, 45, 51, 52 and 58, while speciﬁc primers for the gene
encoding for glyceraldehyde-3-phosphate dehydrogenase
were used as an internal control [17] (Table 1). PCR prod-
ucts were denatured in 0.13 N NaOH and hybridized to an
immobilized HPV probe array using an extended reverse
line-blot assay for HPV genotyping (Roche Molecular Sys-
tems, Inc., Alameda, CA, USA) of nine high-risk HPVs (types
16, 18, 31, 33, 35, 45, 51, 52 and 58), as classiﬁed by Begum
et al. [3].
Tissue microarray
The tissue microarray (TMA) construction was performed as
described by Kuefer et al. [18]. Cervical tumour samples
were embedded in a virgin parafﬁn TMA block using a
manual tissue arrayer (Beecher Instruments, Silver Spring,
MD, USA). Each block was assembled without prior knowl-
edge of associated clinical or pathological staging information.
An average of two TMA cores (range two to six) 1.0 mm in
diameter were sampled from a cohort of 44 Syrian patients
diagnosed with cervical carcinoma. After construction, 4-lm
sections were cut and stained with haematoxylin and eosin
to verify the histological diagnosis. Slides of the ﬁnished
blocks were used for immunohistochemistry analysis.
Immunohistochemistry
Immunohistochemical procedures examining the expression
of Id-1, Id-2, Id-3, Id-4 and E6 were carried out using the fol-
lowing standard procedures. The protein expression levels
and immunolocalization of Id-1, Id-2, Id-3, Id-4 and E6 in the
TMA of Syrian cervical tumour specimens were analysed by
mounting 4-lm sections of the TMA on saline-coated slides
(Sigma, St Louis, MO, USA), which were subsequently dried
overnight at 37C. The TMA sections were then deparafﬁ-
nized in graded alcohol, rehydrated, and boiled in 10 mM cit-
rate buffer (pH 6.0) for antigen retrieval. The TMA slides
were subsequently incubated for 32 min at 37C with pri-
mary polyclonal rabbit antihuman Id-1, Id-2, Id-3 and Id-4
antibodies (sc-488, sc-489, sc-490 and sc-491, respectively;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilu-
tion of 1:25, or E6 (mouse monoclonal; clone C1P5; Calbio-
chem, ON, Canada) at a dilution of 1:20, using the NexES
automated immunostainer (Ventana Medical System, Tucson,
AZ, USA). The automated Ventana Medical System uses an
indirect biotin–avidin system with a universal biotinylated
immunoglobulin secondary antibody. Diaminobenzidine was
used as a chromogen, and slides were counterstained with
haematoxylin prior to mounting. All staining procedures
were performed according to the manufacturers’ recommen-
dations. Negative controls were obtained using speciﬁc
blocking peptides from Santa Cruz Biotechnology with anti-
Id antibodies at a ratio of 10:1 and by omitting the speciﬁc
primary antibody for E6.
Following immunohistochemistry, all TMA slides were
manually scored for Id-1, Id-2, Id-3, Id-4 and E6 expression
and categorized using a three-tiered system (0 = negative,
1 = weak, 2 = strong) by two independent observers.
Results
In order to categorize the presence of high-risk HPV in
human cervical cancer in Syrian women, we investigated the
presence of high-risk HPV types 16, 18, 31, 33 35, 45, 51, 52
TABLE 1. Gene-speciﬁc primer sets for E7 genes of high-risk
HPVs used for PCR ampliﬁcation
HPV types Region Primers
16 E7 5¢-ATGCATGGAGATACACCTACATTGCAT-3¢
5¢-GTTTCTGAGAACAGATGGGGCACAC-3¢
18 E6 5¢-GCTTTGAGGATCCAACACGG-3¢
5¢-TGCAGCACGAATGGCACTGG-3¢
31 E7 5¢-GGGCTCATTTGGAATCGTGTG-3¢
5¢-AACCATTGCATCCCGTCCCC-3¢
33 E7 5¢-TGAGGATGAAGGCTTGGACC-3¢
5¢-TGACACATAAACGAACTGTG-3¢
35 E7 5¢-CTATTGACGGTCCAGCT-3¢
5¢-TACACACAGACGTAGTGTCG-3¢
45 E7 5¢-CCC ACG AGC CGA ACC ACA G-3¢
5¢-TCT AAG GTC CTC TGC CGA GC-3¢
51 E7 5¢-TAC GTG TTA CAG AAT TGA AG-3¢
5¢-AAC CAG GCT TAG TTC GCC CAT T-3¢
52 E7 5¢-GCA GAA CAA GCC ACA AGC AA-3¢
5¢-TAG AGT ACG AAG GTC CGT CG-3¢
58 E7 5¢-CGA GGA TGA AAT AGG CTT GG-3¢
5¢-ACA CAA ACG AAC CGT GGT GC-3¢
Primers speciﬁc for the glyceraldehyde-3-phosphate dehydrogenase gene, 5¢-GA-
AGGC-CATGCCAGTGAGCT-3¢ and 5¢-CCGGGAAACTGTGGCGTGAT-3¢,
were used as an internal control.
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and 58 in a cohort of 44 cervical tumour samples from
Syrian women by PCR analysis, using speciﬁc primers for the
E7 gene (Table 1). The study revealed that 42 (95%) of the
44 samples were HPV positive and all of these positive speci-
mens were co-infected with more than one HPV type. The
most prevalent high-risk HPVs among the infected samples
were types 33 (24/44), 16 (21/44), 18 (18/44), 45 (17/44), 52
(13/44), 58 (11/44), 35 (9/44), 51 (7/44) and 31 (5/44)
(Fig. 1).
The association between the presence of high-risk HPV
types 16, 18, 31, 33, 35, 45, 51, 52 and 58 and Id gene
expression in relation to tumour aggressiveness in cervical
cancer in these 44 Syrian women was then investigated.
We examined the expression of the Id-1, Id-2, Id-3, Id-4
and the E6 oncoprotein in high-risk HPVs by immunohisto-
chemistry in all the cervical tissue samples, using TMA
methodology (Fig. 2). It was found that E6 expression
correlated with Id-1 expression in 95% of human cervical
cancers, which were invasive carcinomas in the majority of
cases (Figs 2 and 3). Overexpression of Id-1 was detected
in 36 patients, Id-1 expression was weak in four cases and
absent in four cases.
By contrast, overexpression of Id-2 was observed in ten
samples, weak expression observed in 22 cases and no
expression of Id-2 was found in 12 cases. Genes Id-3 and
Id-4 demonstrated strong expression in only one sample and
weak expression in 16 and 13 cases, respectively, whereas
no expression of these genes was found in the rest of the
samples.
In order to conﬁrm the association between E6/E7 of
HPV types 16, 18, 31, 33, 35, 45, 51, 52, 58 and Id-1, the
presence of E7 in these viruses was investigated by PCR
using speciﬁc primers for this gene (Table 1). This analysis
showed that high-risk HPV types 16, 18, 31, 33, 35, 45, 51,
52 and 58 were present in the majority of invasive cervical
cancer tissues and their presence was associated with over-
expression of Id-1 but not Id-2, Id-3 or Id-4 (Fig. 2).
Discussion
This is the ﬁrst study to examine the relationship between
the presence of high-risk HPVs and tumour aggressiveness in
cervical cancer in Syrian women. Earlier studies reported
that HPV types 16, 18, 31, 33, 35, 45, 52 and 58 are the
most frequent high-risk HPVs in cervical cancers throughout
the world [2]. Parallel studies have shown that HPV types
16, 18, 31, 33, 35, 45, 52 and 56 are the most common
HPVs in women living in Europe and North America [2,19].
Similarly, studies on the presence of high-risk HPVs in North
African and Middle Eastern women have revealed that HPV
types 16, 18, 45, 35 and 33 are generally present in cervical
cancer in these women [20–22]. In this study, we report
that high-risk HPVs are present in 95% of cervical cancers in
Syrian women.
HPV type 33
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FIG. 1. Representative PCR reactions for E7 of high-risk HPVs in
ten different cervical cancer tissue samples. E7 of high-risk HPV
types (33, 16, 18 and 45) are present frequently in comparison with
HPV type 31 in these patient samples (1–10; N, negative control).
2.0
1.5
1.0
E6
 o
f h
ig
h-
ri
sk
 H
PV
 a
nd
 Id
 g
en
e
ex
pr
es
sio
n 
(95
%
 C
I)
0.5
0.0
Gene targets
44
Id-4
44
Id-3
44
Id-2
44
Id-1
44
E6
N =
2.5
FIG. 2. Correlation between the expression of E6 of high-risk HPVs
and of Id-1, Id-2, Id-3 and Id-4 in human cervical cancer tissue sam-
ples. E6 of high-risk HPV 16, 18, 31, 33, 35, 45, 51, 52 and 58
expression was compared with Id-1, Id-2, Id-3 and Id-4 expression in
a cohort of 44 cervical cancer samples using immunohistochemistry
as described in Materials and Methods. CIs (95%) show normalized
mean protein intensity units of E6, Id-1, Id-2, Id-3 and Id-4 as deter-
mined by quantitative evaluation of immunohistochemistry. The mean
is represented by square bars, ±SE. E6 expression of these high-risk
HPVs is associated with Id-1 overexpression, but not with Id-2, Id-3
and Id-4, in these samples (p <0.001). The presence of high-risk HPV
types 16, 18, 31, 33, 35, 45, 51, 52 and 58 was conﬁrmed by PCR
using gene-speciﬁc primers for E6/E7 genes.
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Moreover, HPV types 33, 16, 18, 45 and 52 are the pre-
dominant viruses of the high-risk HPV family in these cervical
tumour tissues. Therefore, the prevalence of high-risk HPVs
in cervical cancers of the Syrian women in this study is simi-
lar to those reported in other countries, especially the Mid-
dle East and North Africa. Nevertheless, we believe that
future studies on a larger number of samples will be neces-
sary to conﬁrm the incidence of HPVs in cervical cancer in
patients of Middle Eastern origin.
Evidence available to date suggests that persistent infec-
tion with high-risk HPVs is necessary for cervical precursor
lesions to evolve into invasive carcinomas [2,20,23,24]. On
the other hand, several studies have proposed that Id-1 and
probably Id-3 genes play a crucial role in the progression of
several human cancers, including cervical cancer [12,14,16].
This study reports for the ﬁrst time that the presence of E6/
E7 oncoproteins of HPV types 16, 18, 31, 33, 35, 45, 51, 52
and 58 is associated with Id-1 expression in invasive cervical
cancer tissues from Syrian women. In support of these ﬁnd-
ings, Schindl et al. [12] found that Id-1, but not Id-2 or Id-3,
is expressed in the majority of invasive cervical carcinomas.
Moreover, in Schindl’s study, patients with strong or moder-
ate expression of Id-1 had a signiﬁcantly shorter overall sur-
vival time. Recently, we demonstrated that the presence of
high-risk HPVs is correlated with Id-1 expression in human
invasive and metastatic breast cancer tissues [25], and that
E6/E7 of HPV type 16 regulates Id-1 expression through the
activation of its promoter [17]. The present study suggests
that Id-1, but not Id-2, Id-3 or Id-4, is a downstream target
of E6/E7 of HPV types 16, 18, 31, 33, 35, 45, 51, 52 and 58
in human cervical cancer cells.
In conclusion, high-risk HPV types 16, 18, 31, 33, 35,
45, 51, 52 and 58 were found in the majority of cervical
cancers of Syrian women. Furthermore, HPV types 33, 16,
18, 45 and 52 were shown to be the most dominant
types of HPV infection found in Middle Eastern women,
based on the combination of this investigation and a study
by Castellsague´ et al. [20]. This study has also shown that
Id-1 is a target of E6/E7 oncoproteins of HPV type 16, 18,
31, 33, 35, 45, 51, 52 and 58 in invasive cervical cancer
cells. These ﬁndings provide a new basis for understanding
the mechanisms of high-risk HPV infections and their rela-
tion to human cervical invasive carcinomas. Therefore, the
development of new vaccines that target all of the high-
risk HPVs identiﬁed in this study will be necessary to pre-
vent cervical cancers and their progression. Current HPV
vaccines cover only two high-risk (16 and 18) and two
low-risk (6 and 11) types [26]. Moreover, further research
is required to gain a better understanding of the associa-
tion between HPV infection and cervical cancer progres-
sion.
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FIG. 3. Representative immunohistochemistry
revealing E6 and Id-1 expression in cervical
tumour tissue from high-risk HPVs. The three
different cervical tumour tissue samples were
prepared using tissue miscroarrays and bound
E6 and Id-1 antibodies were visualized using d-
iaminobenzidine staining. Structural features of
the tumour tissue were revealed by haemat-
oxylin and eosin staining. Although the levels
of E6 and Id-1 expression vary between patie-
nts, there is a correlation between high levels
of E6 expression and Id-1 overexpression (ar-
rows) in tissue from individual patients. Magni-
ﬁcation is 200·.
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